

DESCRIPTION

Species Reactivity	Mouse
Specificity	Detects mouse LRIG1 in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human LRIG3 is observed.
Source	Monoclonal Rat IgG _{2A} Clone # 440710
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant mouse LRIG1 Ala37-Thr794 Accession # P70193
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Blockade of Receptor-ligand Interaction Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LRIG1 (formerly LIG-1) is one of three mammalian LRR (leucine-rich repeat) and Ig-like domain-containing type I transmembrane glycoproteins that share 45-50% amino acid (aa) identity (1, 2). All contain fifteen LRRs flanked by cysteine-rich regions and three C-type Ig-like domains within their extracellular domains (ECD) (1, 2). LRIG1 shows the highest expression in liver, brain, stomach, small intestine and skeletal muscle (2). Expression is prominent in certain epithelia and subsets of glial cells (1, 2). Within the cell, LRIG1 is expressed in the perinuclear region as well as on the surface. Mouse LRIG1 is synthesized with a 37 aa signal sequence, a 759 aa ECD, a 21 aa transmembrane sequence and a 295 aa intracellular region that binds the ubiquitin ligase, c-Cbl (3). LRIG1 binds the EGF receptor (ErbB1) or neuregulin receptors (ErbB2, 3 and 4) via either its LRR or Ig-like domains and promotes ubiquitination, internalization and destruction of these receptors (3, 4). Since LRIG1 modulates growth factor receptor expression, there is an inverse relationship between LRIG1 expression and proliferative capacity. Genetic disruption of mouse LRIG1 results in a psoriasis-like epidermal hyperplasia on the tail and facial area, which is consistent with downregulation of LRIG1 in human psoriatic lesions (5). High ratios of EGF R to LRIG1 in human renal cell carcinomas correlate with poor survival (6). In skin squamous cell carcinomas, high LRIG1 expression correlates with a more differentiated state and a survival benefit (7). Mouse LRIG1 ECD shows 90%, 93%, 90% and 87% aa identity with human, rat, bovine and canine LRIG1 ECD, respectively.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.